- Capricor Therapeutics recently reported a larger than expected fourth-quarter fiscal 2025 loss while its CFO Anthony Bergmann sold 25,000 shares on March 31, 2026, under a pre-arranged 10b5-1 trading plan.
- Despite the wider quarterly loss, Capricor underscored investor focus on deramiocel by presenting new HOPE-3 data and highlighting an upcoming August 22, 2026 PDUFA decision for its Duchenne muscular dystrophy cell therapy.
- We’ll now examine how the fresh HOPE-3 data and the August PDUFA decision for deramiocel could reshape Capricor’s investment narrative.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Capricor Therapeutics Investment Narrative Recap
To own Capricor today, you need to believe deramiocel can clear its August 22, 2026 PDUFA hurdle and become a meaningful therapy for Duchenne cardiomyopathy, before cash burn and competition bite too hard. The slightly larger than expected Q4 2025 loss and the CFO’s 10b5-1 share sale do not appear to change that central near term catalyst or the core risk of regulatory delay and financing needs in a pre revenue business.
The most relevant recent development is Capricor’s new HOPE 3 data shared at the Muscular Dystrophy Association conference, which the company views as supportive for the ongoing FDA review of deramiocel. These additional functional and cardiac findings sit directly alongside the August PDUFA date as the key near term trigger for how investors reassess both approval odds and the company’s ability to eventually move beyond persistent losses and dilution risk.
Yet behind the promise of deramiocel, investors should be aware that prolonged regulatory uncertainty and rising R&D costs could still...
Read the full narrative on Capricor Therapeutics (it's free!)
Capricor Therapeutics' narrative projects $134.4 million revenue and $14.4 million earnings by 2028. This requires 115.7% yearly revenue growth and an $84.4 million earnings increase from -$70.0 million today.
Uncover how Capricor Therapeutics' forecasts yield a $50.80 fair value, a 58% upside to its current price.
Exploring Other Perspectives
While consensus highlights regulatory and funding risks, the most optimistic analysts previously modeled US$444.9 million in 2029 revenue and US$285.8 million in earnings, so recent setbacks could meaningfully reset those assumptions.
Explore 7 other fair value estimates on Capricor Therapeutics - why the stock might be worth over 9x more than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your Capricor Therapeutics research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Capricor Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Capricor Therapeutics' overall financial health at a glance.
Curious About Other Options?
Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:
- Uncover the next big thing with 31 elite penny stocks that balance risk and reward.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Outshine the giants: these 22 early-stage AI stocks could fund your retirement.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com